The TpTe interval in lead V1 (87 vs. 71 ms; P=0.017) and TpTe/QT ratio (0.24 vs. 0.19; P=0.018) were significantly higher in high-risk Brugada syndrome patients compared to other Brugada patients.
Observational (n=78)
Are the TpTe interval and TpTe/QT ratio associated with high risk of life-threatening arrhythmias in patients with Brugada syndrome?
The TpTe interval and TpTe/QT ratio in ECG lead V1 are significantly higher in high-risk Brugada syndrome patients, suggesting their potential utility as non-invasive risk markers for life-threatening arrhythmias.
Absolute Event Rate: 87% vs 71%
p-value: p=0.017
AIMS: intervals (TpTe) as a novel ECG parameter for the occurrence of cardiac arrhythmias. METHODS AND RESULTS: Clinical and genetic data of 78 unrelated BrS patients (male: n = 57, age: 45 ± 14 years) were retrospectively analysed for medical history, gene mutation, and ECG parameters (in particular heart rate, PQ, QRS, QT, and TpTe) as obtained after digital measurements. TpTe in ECG lead V1 (87 ± 30 vs. 71 ± 27 ms; P = 0.017) and the TpTe/QT ratio (0.24 vs. 0.19; P = 0.018) were significantly higher in high-risk BrS patients than in other BrS patients. In the other right precordial leads typically indicative for BrS, no significant difference was noted. CONCLUSION: Assessment of the TpTe interval or the TpTe/QT ratio in lead V1 is potentially useful as a non-invasive risk marker for BrS patients with life-threatening arrhythmias.
Zumhagen et al. (Thu,) conducted a observational in Brugada syndrome (n=78). High-risk Brugada syndrome vs. Other Brugada syndrome patients was evaluated on TpTe in ECG lead V1 (p=0.017). The TpTe interval in lead V1 (87 vs. 71 ms; P=0.017) and TpTe/QT ratio (0.24 vs. 0.19; P=0.018) were significantly higher in high-risk Brugada syndrome patients compared to other Brugada patients.